Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy

• DOI: 10.18632/oncotarget.25413
• Publication Date: 2018-05-29T13:49:26Z
• Authors: Angela Santonja; Alfonso Sánchez-M...; Ana Lluch; Maria Rosario Chi...; Joan Albanell; José Ignacio Chacón; Silvia Antolín; José Manuel Jerez; Juan de la Haba; Vanessa de Luque; Cristina Elisabet...; Luis Vicioso; Yéssica Plata; César Luis Ramíre...; Martina Álvarez; Casilda Llácer; Irene Zarcos-Pedr...; Eva Carrasco; Rosalía Caballero; Miguel Martín; Emilio Alba
• Keywords: Carboplatin; Triple-negative breast cancer; Neoadjuvant Therapy; Basal (medicine)

Triple negative breast cancer (TNBC) is a heterogeneous disease with distinct molecular subtypes that differentially respond to chemotherapy and targeted agents. The purpose of this study explore the clinical relevance Lehmann TNBC by identifying any differences in response neoadjuvant among them. We determined gene expression profiling paraffined pre-treatment tumor biopsies from 125 patients treated anthracyclines and/or taxanes +/- carboplatin. explored clinicopathological characteristics their association pathologic complete (pCR) different treatments. global pCR rate was 37%, it unevenly distributed within Lehmann's subtypes. Basal-like 1 (BL1) tumors exhibited highest carboplatin containing regimens (80% vs 23%, p=0.027) were most proliferative (Ki-67>50% 88.2% vs. 63.7%, p=0.02). Luminal-androgen receptor (LAR) achieved lowest all treatments (14.3% 42.7%, p=0.045 when excluding mesenchymal stem-like (MSL) samples) group proliferation (Ki-67≤50% 71% 27%, p=0.002). In our cohort, only LAR phenotype presented non-basal-like intrinsic (HER2-enriched luminal A). present high genetic diversity ranging highly tumors, likely responsive platinum-based therapies, subset chemoresistant low characteristics.